Sanofi (STU:SNW) Beneish M-Score: -2.45 (As of Jun. 24, 2026)


STU:SNW Sanofi SA STU:SNW
87 GF Score
Price €73.65
GF Value €107.22
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi Beneish M-Score?

Sanofi STU:SNW +0.95% 87 Beneish M-Score is -2.45 as of Jun. 24, 2026. GuruFocus rates STU:SNW with a GF Score™ of 87/100 and a GF Value™ of €107.22 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Sanofi ranks worse than 54.01% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sanofi's Beneish M-Score or its related term are showing as below:

STU:SNW' s Beneish M-Score Range Over the Past 10 Years
Min: -2.6   Med: -2.48   Max: -2.34
Current: -2.45

During the past 13 years, the highest Beneish M-Score of Sanofi was -2.34. The lowest was -2.60. And the median was -2.48.


Sanofi Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sanofi's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Beneish M-Score Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.43 -2.58 -2.60 -2.45

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.58 0.00 -2.60 0.00 -2.45

STU:SNW vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sanofi's Beneish M-Score falls into.


STU:SNW
87GF Score
Sanofi SA STU:SNW
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sanofi for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9852+0.528 * 0.9738+0.404 * 1.1236+0.892 * 1.0549+0.115 * 0.7148
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9887+4.679 * 0.002807-0.327 * 1.0832
=-2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €11,046 Mil.
Revenue was €46,716 Mil.
Gross Profit was €33,667 Mil.
Total Current Assets was €30,952 Mil.
Total Assets was €126,805 Mil.
Property, Plant and Equipment(Net PPE) was €11,511 Mil.
Depreciation, Depletion and Amortization(DDA) was €5,678 Mil.
Selling, General, & Admin. Expense(SGA) was €10,242 Mil.
Total Current Liabilities was €28,345 Mil.
Long-Term Debt & Capital Lease Obligation was €15,715 Mil.
Net Income was €7,813 Mil.
Gross Profit was €-3,293 Mil.
Cash Flow from Operations was €10,750 Mil.
Total Receivables was €10,629 Mil.
Revenue was €44,286 Mil.
Gross Profit was €31,081 Mil.
Total Current Assets was €42,588 Mil.
Total Assets was €132,798 Mil.
Property, Plant and Equipment(Net PPE) was €11,601 Mil.
Depreciation, Depletion and Amortization(DDA) was €3,586 Mil.
Selling, General, & Admin. Expense(SGA) was €9,820 Mil.
Total Current Liabilities was €29,162 Mil.
Long-Term Debt & Capital Lease Obligation was €13,436 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11046 / 46716) / (10629 / 44286)
=0.23645 / 0.240008
=0.9852

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(31081 / 44286) / (33667 / 46716)
=0.701825 / 0.720674
=0.9738

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (30952 + 11511) / 126805) / (1 - (42588 + 11601) / 132798)
=0.665132 / 0.591944
=1.1236

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=46716 / 44286
=1.0549

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3586 / (3586 + 11601)) / (5678 / (5678 + 11511))
=0.236123 / 0.330328
=0.7148

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10242 / 46716) / (9820 / 44286)
=0.21924 / 0.221741
=0.9887

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((15715 + 28345) / 126805) / ((13436 + 29162) / 132798)
=0.347463 / 0.320773
=1.0832

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(7813 - -3293 - 10750) / 126805
=0.002807

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sanofi has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.45 mean?
Sanofi (STU:SNW) has a Beneish M-Score of -2.45 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sanofi and its competitors. According to the industry distribution chart, Sanofi ranks #492 out of 911 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Sanofi's Beneish M-Score too high?
Sanofi's current Beneish M-Score is -2.45. Based on the distribution chart, Sanofi ranks #492 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sanofi has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #492 out of 911 companies for Beneish M-Score. This places Sanofi in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sanofi and its competitors. Sanofi's current Beneish M-Score is -2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (STU:SNW) is currently considered Possible Value Trap. The stock's GF Value™ is €107.22, compared to a current price of €73.65 — trading 31.3% below its estimated fair value. The current Beneish M-Score is -2.45. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sanofi (STU:SNW), the current Beneish M-Score is -2.45 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (STU:SNW) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €73.65 is trading 31.3% below its estimated GF Value™ of €107.22. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for STU:SNW:

  • Beneish M-Score: -2.45
  • GF Value™: €107.22 vs. price of €73.65 (31.3% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the STU:SNW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for STU:SNW

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.65
Price
€107.22
GF Value